ThomasCarlAndersonMD

Clinical Trials

• Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Start of enrollment: 2010 Oct 21

  Terminated

  Phase 4

• Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2011 Mar 01

  Completed

  Phase 3

• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 16

  Terminated

  Phase 3

• Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Start of enrollment: 2013 Jan 02

  Terminated

  Phase 3

• Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11

  Completed

  Phase 2

• Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17

  Completed

  Phase 3

• A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22

  Active, not recruiting

  Phase 3

• Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300) Start of enrollment: 2015 Dec 28

  Completed

  Phase 3

• Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02

  Terminated

  Phase 2

• Join now to see all